Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans.

Background: Extended-release naltrexone (NTX) is an opioid antagonist approved for relapse prevention after medical withdrawal. Its therapeutic effect is dependent on the NTX plasma level, and as it decreases, patients may lack protection against relapse and overdose. Therefore, identifying the minimally effective NTX level needed to block opioid-induced subjective effects has important clinical implications.
Methods: This secondary, individual-level analysis of data collected in a human laboratory study was conducted to evaluate the relationship between NTX levels and subjective effects of an intravenously administered 25-mg challenge dose of heroin in non-treatment-seeking participants with opioid use disorder (N = 12). Subjective ratings of drug liking using a 100-mm visual analog scale (VAS) and NTX levels were measured across 6 weeks after participants received a single injection of either extended-release NTX 192 mg (N = 6) or 384 mg (N = 6). Cubic spline mixed-effects models were used to provide 95% prediction intervals for individual changes in liking scores as a function of NTX levels.
Results: Naltrexone levels above 2 ng/mL blocked nearly all VAS ratings of drug liking after intravenous heroin administration. Participants with NTX levels ≥ 2 ng/mL had minimal (≤20 mm) changes from placebo in VAS ratings of drug liking based on 95% prediction intervals. In contrast, NTX levels < 2 ng/mL were associated with greater variability in individual-level subjective responses.
Conclusions: In clinical practice, a plasma level range of 1 to 2 ng/mL is considered to be therapeutic in providing heroin blockade. The current findings suggest that a higher level (>2 ng/mL) may be needed to produce a consistent blockade.
Competing Interests: The following authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: S.D.C.: Alkermes, Clinilabs, Mallinckrodt, Nektar, Opiant, Otsuka, BioXcel, Corbus, GoMedical, Intra-Cellular Therapies, Lyndra, Janssen, Expert Committee on Drug Dependence, and the World Health Organization; A.B.: Alkermes and GoMedical; E.V.N.: Alkermes, Indivior, Braeburn, Pear Therapeutics, CHESS Health, Brainsway, and Camurus. The remaining authors report no conflicts of interest.
(Copyright © 2023 American Society of Addiction Medicine.)